India, Nov. 9 -- Zura Bio Limited (ZURA), a clinical-stage biotechnology company developing treatments for autoimmune and inflammatory diseases, announced Monday that its Phase 2 TibuSHIELD study of tibulizumab (ZB-106) in adults with moderate-to-severe hidradenitis suppurativa (HS) failed to meet its main study goal or key secondary goals.
The study's main goal was to measure the percentage reduction in the number of abscesses and inflammatory nodules (AN) after 16 weeks of treatment. Neither the 300 mg nor the 150 mg dose of tibulizumab met this goal.
The study also failed to meet its key secondary goals, which included HiSCR50 and HiSCR75, measures of improvement in HS symptoms.
TibuSHIELD was a global, randomized, placebo-controlled ...